Does the media prefer PCVX or BCRX?

In the previous week, BioCryst Pharmaceuticals had 1 more articles in the media than Vaxcyte. MarketBeat recorded 3 mentions for BioCryst Pharmaceuticals and 2 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.33 beat BioCryst Pharmaceuticals' score of 0.31 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioCryst Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CYTK or BCRX?

In the previous week, Cytokinetics had 9 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 12 mentions for Cytokinetics and 3 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.31 beat Cytokinetics' score of -0.05 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral BioCryst Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BCRX or ABVX?

In the previous week, Abivax had 4 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 7 mentions for Abivax and 3 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.31 beat Abivax's score of 0.17 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Abivax 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

BioCryst Pharmaceuticals (BCRX) Competitors

$8.17 +0.05 (+0.62%)

Closing price 04:00 PM Eastern

Extended Trading

$8.09 -0.08 (-0.98%)

As of 05:49 PM Eastern

Compare

BCRX vs. APGE, PCVX, CYTK, ABVX, and PRAX

Should you buy BioCryst Pharmaceuticals stock or one of its competitors? BioCryst Pharmaceuticals's main competitors and comparable companies include Apogee Therapeutics (APGE), Vaxcyte (PCVX), Cytokinetics (CYTK), Abivax (ABVX), and Praxis Precision Medicines (PRAX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioCryst Pharmaceuticals compare to Apogee Therapeutics?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, BioCryst Pharmaceuticals had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 3 mentions for BioCryst Pharmaceuticals and 0 mentions for Apogee Therapeutics. BioCryst Pharmaceuticals' average media sentiment score of 0.31 beat Apogee Therapeutics' score of 0.00 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
BioCryst Pharmaceuticals	Neutral
Apogee Therapeutics	Neutral

BioCryst Pharmaceuticals presently has a consensus target price of $20.50, suggesting a potential upside of 155.77%. Apogee Therapeutics has a consensus target price of $126.77, suggesting a potential downside of 6.14%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe BioCryst Pharmaceuticals is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16

BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market.

Apogee Therapeutics has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -40.90%. Apogee Therapeutics' return on equity of -29.88% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
Apogee Therapeutics	N/A	-29.88%	-28.08%

BioCryst Pharmaceuticals has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.34	$263.86M	-$1.50	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A

Summary

BioCryst Pharmaceuticals beats Apogee Therapeutics on 12 of the 16 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Vaxcyte has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -40.90%. Vaxcyte's return on equity of -37.56% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 3.3% of Vaxcyte shares are held by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Vaxcyte has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

In the previous week, BioCryst Pharmaceuticals had 1 more articles in the media than Vaxcyte. MarketBeat recorded 3 mentions for BioCryst Pharmaceuticals and 2 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.33 beat BioCryst Pharmaceuticals' score of 0.31 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCryst Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCryst Pharmaceuticals has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
BioCryst Pharmaceuticals	$874.84M	2.34	$263.86M	-$1.50	N/A

Vaxcyte presently has a consensus target price of $104.40, indicating a potential upside of 85.41%. BioCryst Pharmaceuticals has a consensus target price of $20.50, indicating a potential upside of 155.77%. Given BioCryst Pharmaceuticals' higher probable upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
BioCryst Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

BioCryst Pharmaceuticals beats Vaxcyte on 9 of the 15 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 2.6% of Cytokinetics shares are held by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cytokinetics has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

In the previous week, Cytokinetics had 9 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 12 mentions for Cytokinetics and 3 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.31 beat Cytokinetics' score of -0.05 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
BioCryst Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCryst Pharmaceuticals has a net margin of -40.90% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-1,321.12%	N/A	-51.01%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

Cytokinetics currently has a consensus price target of $106.00, suggesting a potential upside of 63.86%. BioCryst Pharmaceuticals has a consensus price target of $20.50, suggesting a potential upside of 155.77%. Given BioCryst Pharmaceuticals' higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85
BioCryst Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

BioCryst Pharmaceuticals has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	91.43	-$784.96M	-$7.22	N/A
BioCryst Pharmaceuticals	$874.84M	2.34	$263.86M	-$1.50	N/A

Summary

BioCryst Pharmaceuticals beats Cytokinetics on 11 of the 16 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Abivax?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Abivax (NASDAQ:ABVX) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BioCryst Pharmaceuticals has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.34	$263.86M	-$1.50	N/A
Abivax	N/A	N/A	-$380.27M	-$6.06	N/A

In the previous week, Abivax had 4 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 7 mentions for Abivax and 3 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.31 beat Abivax's score of 0.17 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abivax	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCryst Pharmaceuticals has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, Abivax has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

BioCryst Pharmaceuticals currently has a consensus target price of $20.50, suggesting a potential upside of 155.77%. Abivax has a consensus target price of $156.69, suggesting a potential upside of 66.52%. Given BioCryst Pharmaceuticals' higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Abivax has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -40.90%. BioCryst Pharmaceuticals' return on equity of -86.89% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
Abivax	N/A	-91.69%	-71.96%

Summary

BioCryst Pharmaceuticals beats Abivax on 10 of the 16 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

BioCryst Pharmaceuticals has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	957.63	-$303.27M	-$12.93	N/A
BioCryst Pharmaceuticals	$874.84M	2.34	$263.86M	-$1.50	N/A

Praxis Precision Medicines presently has a consensus target price of $612.42, indicating a potential upside of 108.83%. BioCryst Pharmaceuticals has a consensus target price of $20.50, indicating a potential upside of 155.77%. Given BioCryst Pharmaceuticals' higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95
BioCryst Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, BioCryst Pharmaceuticals had 1 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 3 mentions for BioCryst Pharmaceuticals and 2 mentions for Praxis Precision Medicines. BioCryst Pharmaceuticals' average media sentiment score of 0.31 beat Praxis Precision Medicines' score of 0.00 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCryst Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Praxis Precision Medicines has a beta of 2.79, indicating that its share price is 179% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Praxis Precision Medicines has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -40.90%. Praxis Precision Medicines' return on equity of -34.15% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

BioCryst Pharmaceuticals beats Praxis Precision Medicines on 10 of the 17 factors compared between the two stocks.

Get BioCryst Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCRX vs. The Competition

Export

Metric	BioCryst Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.09B	$3.84B	$7.10B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-5.45	12.99	274.61	26.05
Price / Sales	2.39	1,288.54	601.02	89.39
Price / Cash	6.73	121.76	77.38	51.25
Price / Book	-14.33	16.63	10.92	6.31
Net Income	$263.86M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-4.89%	-3.06%	-2.11%	-1.67%
1 Month Performance	-19.67%	-10.76%	-6.34%	-3.94%
1 Year Performance	11.46%	21.10%	8.81%	2.77%

BioCryst Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCRX BioCryst Pharmaceuticals	2.3498 of 5 stars	$8.17 +0.6%	$20.50 +150.9%	+10.2%	$2.09B	$874.84M	N/A	435	Analyst Forecast
APGE Apogee Therapeutics	0.8304 of 5 stars	$135.07 flat	$126.77 -6.1%	N/A	$8.40B	N/A	N/A	91
PCVX Vaxcyte	2.1619 of 5 stars	$58.27 +3.7%	$104.40 +79.2%	+47.4%	$8.36B	N/A	N/A	507	Insider Trade
CYTK Cytokinetics	2.1594 of 5 stars	$66.16 +2.3%	$103.37 +56.2%	+17.5%	$8.05B	$88.04M	N/A	673
ABVX Abivax	2.7219 of 5 stars	$96.85 +6.4%	$156.69 +61.8%	+15.4%	$7.95B	N/A	N/A	69

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCRX) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioCryst Pharmaceuticals (BCRX) Competitors

BCRX vs. APGE, PCVX, CYTK, ABVX, and PRAX

How does BioCryst Pharmaceuticals compare to Apogee Therapeutics?

Summary

How does BioCryst Pharmaceuticals compare to Vaxcyte?

Summary

How does BioCryst Pharmaceuticals compare to Cytokinetics?

Summary

How does BioCryst Pharmaceuticals compare to Abivax?

Summary

How does BioCryst Pharmaceuticals compare to Praxis Precision Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX vs. The Competition

BioCryst Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioCryst Pharmaceuticals (BCRX) Competitors

BCRX vs. APGE, PCVX, CYTK, ABVX, and PRAX

How does BioCryst Pharmaceuticals compare to Apogee Therapeutics?

Do institutionals & insiders hold more shares of BCRX or APGE?

Does the media prefer BCRX or APGE?

Do analysts rate BCRX or APGE?

Which has more volatility and risk, BCRX or APGE?

Is BCRX or APGE more profitable?

Which has higher valuation & earnings, BCRX or APGE?

Summary

How does BioCryst Pharmaceuticals compare to Vaxcyte?

Is PCVX or BCRX more profitable?

Do insiders & institutionals believe in PCVX or BCRX?

Which has more volatility & risk, PCVX or BCRX?

Does the media prefer PCVX or BCRX?

Which has preferable valuation and earnings, PCVX or BCRX?

Do analysts rate PCVX or BCRX?

Summary

How does BioCryst Pharmaceuticals compare to Cytokinetics?

Do institutionals & insiders have more ownership in CYTK or BCRX?

Which has more risk and volatility, CYTK or BCRX?

Does the media refer more to CYTK or BCRX?

Is CYTK or BCRX more profitable?

Do analysts prefer CYTK or BCRX?

Which has higher earnings & valuation, CYTK or BCRX?

Summary

How does BioCryst Pharmaceuticals compare to Abivax?

Do insiders and institutionals hold more shares of BCRX or ABVX?

Which has better earnings & valuation, BCRX or ABVX?

Does the media favor BCRX or ABVX?

Which has more volatility and risk, BCRX or ABVX?

Do analysts recommend BCRX or ABVX?

Is BCRX or ABVX more profitable?

Summary

How does BioCryst Pharmaceuticals compare to Praxis Precision Medicines?

Which has stronger valuation & earnings, PRAX or BCRX?

Do analysts recommend PRAX or BCRX?

Does the media refer more to PRAX or BCRX?

Which has more risk and volatility, PRAX or BCRX?

Is PRAX or BCRX more profitable?

Do insiders and institutionals believe in PRAX or BCRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX vs. The Competition

BioCryst Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools